Vanderbilt Clinical Trials

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Purpose

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.

Conditions

Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma

Eligibility

Eligible Ages: Over 18 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Histologically documented metastatic or unresectable urothelial carcinoma. Both transitional cell and mixed transitional cell histologies are allowed, provided urothelial component is ≥ 50%. - At least 1 measurable target lesion per RECIST v1.1. - Must be ineligible to receive cisplatin. Patients ineligible for any platinum-based chemotherapy are allowed. - Known FGFR3 mutation or rearrangement confirmed by the central laboratory prior to randomization. - Central laboratory test result of PD-L1 status is mandatory at screening. - Have received no prior systemic chemotherapy for metastatic or unresectable urothelial carcinoma (except adjuvant platinum-based chemotherapy following radical cystectomy, with recurrence > 12 months from completion of therapy, or neo-adjuvant platinum-based chemotherapy, with recurrence > 12 months since completion of therapy). - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. - Willingness to avoid pregnancy or fathering children.

Exclusion Criteria

Prior receipt of a selective FGFR inhibitor for any indication or reason. - Prior receipt of an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor. - Receipt of anticancer medications or investigational drugs for unresectable and/or metastatic disease. - Concurrent anticancer therapy, except for treatment allowed per protocol. - Has disease that is suitable for local therapy administered with curative intent. - Has tumor with any neuroendocrine or small cell component. - Current evidence of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination. - Has received prior radiotherapy to a metastatic site without the use of chemotherapy radiosensitization within 3 weeks of the first dose of study treatment, with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks before the start of study treatment. - Has central nervous system metastases, unless the participant has completed local therapy (eg, whole brain radiation therapy, surgery, radiosurgery) and has discontinued use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. - Known additional malignancy that is progressing or required active treatment within the past 3 years - Laboratory values outside the protocol-defined range at screening. - Clinically significant or uncontrolled cardiac disease. - History of autoimmune disease that has required systemic treatment in past 2 years.

Study Design

Phase: Phase 2
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental Pemigatinib + Pembrolizumab	Combination of pemigatinib (13.5 milligrams [mg] once a day orally) plus pembrolizumab (200 mg every 3 weeks [Q3W] intravenously [IV])	Drug: Pemigatinib 13.5 mg once a day orally Other names: INCB054828 Drug: Pembrolizumab 200 mg Q3W intravenously Other names: Keytruda®
Experimental Pemigatinib	Pemigatinib (13.5 mg once a day orally) alone	Drug: Pemigatinib 13.5 mg once a day orally Other names: INCB054828 Drug: Pembrolizumab 200 mg Q3W intravenously Other names: Keytruda®
Active Comparator Standard of Care	Either gemcitabine plus carboplatin or pembrolizumab as standard of care. Gemcitabine 1000 mg/meters squared (m^2) IV over 30 minutes on Days 1 and 8, followed by carboplatin (dosed to target area under the concentration-time curve [AUC] of 5 mg/milliliters [mL]/minute [min] or 4.5 mg/mL/min if required per local guidelines) on Day 1 or 2 of each 3-week cycle. Pembrolizumab 200 mg IV on Day 1 of each 21-day treatment cycle for up to 35 cycles or disease progression.	Drug: Gemcitabine 1000 mg/m^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle Drug: Carboplatin Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle

More Details

Status: Terminated
Sponsor: Incyte Corporation

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.